|
【结 构 式】 
|
【分子编号】46735 【品名】(2S,3R,4S,6R)-2-[((3aS,4R,7R,8S,9S,10R,11S,13R,15R,15aR)-4-ethyl-8-hydroxy-3a,7,9,11,13,15-hexamethyl-2,6,14-trioxo-11-[[(E)-3-(3-quinolinyl)-2-propenyl]oxy]tetradecahydro-2H-oxacyclotetradecino[4,3-d][1,3]oxazol-10-yl)oxy]-4-(dimethylamino)-6-methyltetrahydro-2H-pyran-3-yl benzoate 【CA登记号】 |
【 分 子 式 】C49H65N3O11 【 分 子 量 】872.06872 【元素组成】C 67.49% H 7.51% N 4.82% O 20.18% |
与该中间体有关的原料药合成路线共 1 条
合成路线1
该中间体在本合成路线中的序号：(VIII)The treatment of cyclic carbamate (VII) with HCl in ethanol produces the cleavage of the cladinosyl sugar moiety, resulting in the 3-hydroxyerythromycin derivative (VIII), which is oxidized with N-chlorosuccinimide (NCS) in dichloromethane to yield the 3-oxoerythromycin A derivative (IX). Finally, this compound is debenzoylated in refluxing methanol.
| 【1】 Process for preparing 6-O-substd. erythromycin derivs.. WO 0078773 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (VII) | 46732 | (2S,3R,4S,6R)-2-[((3aS,4R,7R,8R,9R,10R,11S,13R,15R,15aR)-8-[[(2R,4R,5S,6S)-5-(acetoxy)-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-4-ethyl-3a,7,9,11,13,15-hexamethyl-2,6,14-trioxo-11-[[(E)-3-(3-quinolinyl)-2-propenyl]oxy]tetradecahydro-2H-oxacyclotetradecino[4,3-d][1,3]oxazol-10-yl)oxy]-4-(dimethylamino)-6-methyltetrahydro-2H-pyran-3-yl benzoate | C59H81N3O15 | 详情 | 详情 | |
| (VIII) | 46735 | (2S,3R,4S,6R)-2-[((3aS,4R,7R,8S,9S,10R,11S,13R,15R,15aR)-4-ethyl-8-hydroxy-3a,7,9,11,13,15-hexamethyl-2,6,14-trioxo-11-[[(E)-3-(3-quinolinyl)-2-propenyl]oxy]tetradecahydro-2H-oxacyclotetradecino[4,3-d][1,3]oxazol-10-yl)oxy]-4-(dimethylamino)-6-methyltetrahydro-2H-pyran-3-yl benzoate | C49H65N3O11 | 详情 | 详情 | |
| (IX) | 46736 | (2S,3R,4S,6R)-2-[((3aS,4R,7R,9R,10R,11S,13R,15R,15aR)-4-ethyl-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-11-[[(E)-3-(3-quinolinyl)-2-propenyl]oxy]tetradecahydro-2H-oxacyclotetradecino[4,3-d][1,3]oxazol-10-yl)oxy]-4-(dimethylamino)-6-methyltetrahydro-2H-pyran-3-yl benzoate | C49H63N3O11 | 详情 | 详情 |
Extended Information